ZUG, Switzerland and BOSTON, Feb. 11, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical ...

Gene therapies to treat rheumatoid arthritis have evolved slowly, but one is ready to move into human trials and an ...

Why are CRISPR companies not OK? Will Robert F. Kennedy Jr. keep his promises if he's confirmed to lead the Department of ...

A UCO team has applied the genome editing technique, which garnered a Nobel Prize in Chemistry in 2020, to unravel the ...

The innovation, he says, could transform the way scientists measure and address genomic breaks in gene-editing systems.

Investing in stocks that aren't performing well can be a good move, but only if there are good reasons to think they will recover. That isn't the case for many companies that have lagged broader ...

While billions pour into pharmaceutical biotech, officials and experts warn there’s much less private investment in products more relevant to the military, like body armor materials, anti-corrosion ...

Potent in vivo gene editing in skeletal muscle of non-human primates by a novel, ultracompact CRISPR system delivered via a single AAV vector.

Gene editing gives scientists “a fast way of creating new varieties of plants,” he says. CRISPR-based editing fulfills another important purpose. Academic scientists, in particular ...

A £1.65 million treatment has been approved for use for some NHS patients, offering some with an inherited blood disorder ...

Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine ...

Around 1,700 people could be eligible for the one-time treatment, which is seen as a less risky alternative to a donor stem ...